PONVORY® (ponesimod) PRESCRIBER'S CHECKLIST

Important points to remember before, during, and after treatment

Adverse events should be reported. This medicinal product is subject to additional monitoring and it is therefore important to report any suspected adverse events related to this medicinal product. Healthcare professionals are asked to report suspected adverse events via: HPRA Pharmacovigilance Website: www.hpra.ie. Adverse events should also be reported to Janssen Sciences Ireland UC on 1800 709 122 or email dsafety@its.jnj.com

EM-82747 I December 2021 Marketing authorisation holder: Janssen-Cilag International NV, Turnhoutseweg 30, B-2340, Beerse, Belgium © 2021 Janssen Sciences Ireland UC



PHARMACEUTICAL COMPANIES OF Johnson Johnson

Introduction to the Prescriber's checklist

This guide provides essential information on the most important identified and potential risks associated with PONVORY[®] and the activities required to minimise these risks (as defined within the PONVORY[®] Risk Minimisation Plan).

Reading this material is essential to ensure the safe and effective use of PONVORY® and appropriately manage important selected risks.

This checklist does not contain all of the information related to the adverse drug reaction profile of PONVORY®, or the relevant prescribing information. The prescriber's checklist should therefore be read in conjunction with the PONVORY® Summary of Product Characteristics (SmPC). For more detailed guidance on PONVORY®, please refer to the SmPC at: <u>www.medicines.ie</u>.

A patient/caregiver guide and a pregnancy-specific patient reminder card have also been developed as part of the risk minimisation plan and should be used to inform your discussion with the patient.

Therapeutic indication:

PONVORY® is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features.

Contraindications:

PONVORY® is contraindicated in patients who have:

- Hypersensitivity to the active substance or to any of the excipients
- An immunodeficient state
- Patients who in the last 6 months experienced myocardial infarction, unstable angina, stroke, transient ischaemic attack (TIA), decompensated heart failure requiring hospitalisation, or New York Heart Association (NYHA) Class III or IV heart failure
- Presence of Mobitz Type II second-degree atrioventricular (AV) block, third-degree AV block, or sick sinus syndrome, unless the patient has a functioning pacemaker
- Severe active infections or active chronic infections
- Active malignancies
- Moderate or severe hepatic impairment (Child-Pugh Class B and C respectively)
- Become pregnant and in women of childbearing potential not using effective contraception

Not recommended:

- Patients with unstable ischemic heart disease, cardiac decompensated failure occurring more than 6 months prior to treatment initiation, history of cardiac arrest, cerebrovascular disease (TIA, stroke occurring more than 6 months prior to treatment initiation), and uncontrolled hypertension, since significant bradycardia may be poorly tolerated in these patients, treatment is not recommended
- Ponvory has not been studied in children and adolescents, therefore it is not recommended for use in children and adolescents aged less than 18 years

Recommended steps to managing patients on PONVORY® (ponisemod)

This checklist is intended to assist in the management of patients being treated with PONVORY[®]. Important points to remember before, during, and after treatment are included.

Patient's name: Date of birth:	
Consultant:	
Hospital Number:	

PRIOR TO INITIATING TREATMENT


Man	Mandatory requirements before initiating treatment	
	Perform an electrocardiogram (ECG) to determine whether any pre-existing cardiac abnormalities are present First-dose monitoring is recommended for patients with certain pre-existing cardiac conditions:	
	• Sinus bradycardia (HR <55 beats per minute [bpm])	
	First- or second-degree (Mobitz Type I) AV block; or	
	• A history of myocardial infarction or heart failure occurring more than 6 months prior to treatment	
	 Consult a cardiologist before initiation of PONVORY® in the following patients to determine the overall benefit- risk and the most appropriate monitoring strategy: Patients with significant QT prolongation (QTc >500 ms) or who are already being treated with QT- prolonging medicinal products with known arrhythmogenic properties (risk of torsades de pointes) Patients with atrial flutter/fibrillation or arrhythmias treated with Class Ia (e.g. quinidine, procainamide) or 	
	 Class III (e.g. amiodarone, sotalol) anti-arrhythmic medicinal products Treatment is not recommended in patients with the following conditions as they may not tolerate significant bradycardia: unstable ischaemic heart disease; previous cardiac arrest; decompensated heart failure or cardiovascular disease (stroke or TIA) occurring more than 6 months before starting PONVORY[®]; or uncontrolled hypertension. 	
	 Patients with a history of Mobitz Type II second-degree AV block or higher-grade AV block, sick-sinus syndrome, or sinoatrial heart block 	
	Patients with a history of recurrent syncope or symptomatic bradycardia	
	 Patients receiving concurrent therapy with drugs that decrease heart rate (HR) (e.g. beta blockers, non-dihydropyridine calcium channel blockers [diltiazem and verapamil] and other drugs that may decrease HR, such as digoxin); consider the need to switch to non-HR-lowering medicinal products Concomitant use of these medicinal products during PONVORY[®] initiation may be associated with severe bradycardia and heart block 	
	Review results of a recent (obtained within 6-months prior to treatment initiation or after discontinuation of prior multiple sclerosis therapy) full blood count (FBC) with differential white count (including absolute lymphocyte count)	
	Review results of a recent (within 6 months prior to treatment initiation) liver function test for transaminase and bilirubin levels	

Obtain ophthalmic evaluation of the fundus, including the macula, prior to treatment initiation. PONVORY® should not be initiated in patients with macular oedema until resolution
Instruct patients to report changes in vision
A pregnancy test is recommended before treatment in all women of childbearing potential
Counsel women of childbearing potential on the potential risk of teratogenicity and the need for effective contraception during treatment with PONVORY® and for at least 1 week following treatment discontinuation
Counsel women of childbearing potential to discontinue treatment with PONVORY® at least 1 week before attempting to conceive
• Explain to the patient that their disease activity may return when treatment with PONVORY® is discontinued due to pregnancy or attempting to conceive
Instruct women receiving PONVORY® that they should not breastfeed
Perform a varicella zoster virus (VZV) antibody test in patients without a confirmed history of varicella or adequate vaccination against VZV
• A full course of vaccination for antibody-negative patients with VZV vaccine is recommended prior to commencing treatment with ponesimod
 VZV vaccination is only indicated if the VZV antibody test is negative
• The full course of VZV vaccination should be completed at least 4 weeks before starting PONVORY®
Initiation of treatment with PONVORY® should be delayed in patients with severe active infection until resolution
Review current or prior medications. If patients are taking antineoplastic, immunosuppressive, or immune- modulating therapies, or if there is a history of prior use of these medicinal products, consider possible unintended additive effects on the immune system before treatment initiation

ROUTINE FIRST-DOSE MONITORING

Cardiology advice on monitoring should be followed if necessary.

If first-dose monitoring for patients with pre-existing cardiac conditions is required, follow the steps outlined below:



bpm, beats per minute; ECG, electrocardiogram; HR, heart rate; QTc, Heart-rate-corrected QT interval.

The patient does not have applicable pre-existing cardiac conditions and therefore first-dose monitoring is not required

TREATMENT INITIATION (INCLUDING RE-INITIATION CRITERIA)

Dose escalation at treatment initiation

Initiate treatment with the 14-day treatment initiation pack. Start treatment on Day 1 with one 2 mg tablet orally once daily and progress with the 14-day titration schedule outlined in the following diagram:

Titration day	Daily dose
Day 1 and 2	2 mg
Day 3 and 4	3 mg
Day 5 and 6	4 mg
Day 7	5 mg
Day 8	6 mg
Day 9	7 mg
Day 10	8 mg
Day 11	9 mg
Day 12, 13 and 14	10 mg

• After dose titration is complete, the recommended maintenance dose of PONVORY® is one 20 mg tablet taken orally once daily.

Re-initiation of PONVORY® therapy following treatment interruption during dose titration or maintenance period

- If fewer than 4 consecutive doses are missed, resume treatment with the first missed dose
- **If 4 or more consecutive doses are missed**, re-initiate treatment with Day 1 (2 mg) of the titration regimen (using a new treatment initiation pack)
 - The same first-dose monitoring as for treatment initiation is recommended when 4 or more consecutive doses of PONVORY® are missed during the titration or maintenance periods in patients with pre-existing cardiac conditions

DURING TREATMENT

Ass •	ess FBC periodically during PONVORY® treatment Absolute lymphocyte counts <0.2×10°/L, if confirmed, should lead to interruption of PONVORY® therapy until
	the level reaches >0.8×10 ⁹ /L, after which re-initiation of PONVORY® can be considered
Considera	tions relating to immunosuppressive effect
imn	efully monitor patients, especially those with concurrent conditions or known risk factors, such as previous nunosuppressive therapy. Discontinuation of treatment in patients at increased risk of infections or ignancies should be considered on a case-by-case basis
Cor	nsider suspension of treatment during serious infection
	efully consider the risk of synergistic immunosuppressive effects when co-prescribing antineoplastic, nunomodulatory or immunosuppressive therapies
Mor	nitor patients for skin malignancies:
•	Suspension of treatment should be considered in those with serious infections
•	Caution patients against exposure to UV light and sunlight without protection
•	Ensure patients are not receiving concomitant phototherapy with ultraviolet B (UVB) radiation or psoralen and ultraviolet A photochemotherapy (PUVA)
•	Patients with pre-existing skin disorders and patients with new or changing skin lesions should be referred to a dermatologist to for advice on management
-	ilance for signs and symptoms of infection is recommended. Instruct patients to report signs and symptoms of actions immediately to their prescriber during treatment, and for up to 1 week after the last dose of PONVORY®
•	Cases of fatal cryptococcal meningitis (CM) and disseminated cryptococcal infections have been reported in patients treated with other sphingosine-1-phosphate (S1P) receptor modulators
	• Suspend treatment with PONVORY® if CM is suspected until cryptococcal infection has been excluded
	Initiate appropriate treatment if CM is diagnosed
•	Cases of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the John Cunningham polyoma virus, have been reported in patients treated with another S1P receptor modulator and other MS therapies. Physicians should be vigilant for clinical signs and symptoms or MRI findings suggestive of PML
	 Suspend treatment with PONVORY[®] if PML is suspected until PML has been excluded
	Discontinue treatment with PONVORY® if PML is confirmed
	of live attenuated vaccines may carry a risk of infection and should therefore be avoided during treatment and up to 1 week after its discontinuation If the use of live attenuated vaccines during treatment with PONVORY® is required, treatment should be

paused 1 week prior and for 4 weeks after a planned vaccination

Ophthalmic evaluation	
	Obtain an ophthalmic evaluation of the fundus, including the macula, at any time if a patient reports any change in vision while on PONVORY® therapy
	Instruct patients to report changes in vision
	Evaluate patients who present with visual symptoms of macular oedema
	Discontinue treatment with PONVORY® if macular oedema is confirmed
	Consider the potential benefits and risks of PONVORY® after resolution of macular oedema before treatment re-initiation
	Conduct regular follow-up examinations of the fundus, including the macula, in patients with a history of uveitis or diabetes mellitus
For w	omen of childbearing potential
	Repeat pregnancy tests at suitable intervals during treatment
	Before initiation and during treatment with PONVORY®, counsel women of childbearing potential on the possibility of serious risk to the foetus during treatment with PONVORY®, using the pregnancy-specific patient reminder card
	Instruct women of childbearing potential to use effective contraception during treatment with PONVORY® and for at least 1 week following treatment discontinuation
	Counsel women of childbearing potential to discontinue treatment with PONVORY® at least 1 week before attempting to conceive
	• Explain to the patient that their disease activity may return when treatment with PONVORY® is discontinued due to pregnancy or attempting to conceive
	Immediately discontinue treatment with PONVORY® if a woman becomes pregnant during treatment. Provide medical advice regarding the risk of harmful effects to the foetus associated with PONVORY® treatment and ensure follow-up examinations are performed
	Instruct women receiving PONVORY® that they should not breastfeed
	If a pregnancy occurs during treatment with PONVORY®, regardless of it being associated with an adverse event or not, please report it to Janssen-Cilag Limited on 01494 567447 or at dsafety@its.jnj.com.
	 Janssen has a developed a Pregnancy Outcomes Enhanced Monitoring (POEM) programme designed to collect information about pregnancy in patients exposed to PONVORY[®] immediately before or during pregnancy and on infant outcomes 12 months post-delivery
	 Physicians are encouraged to enrol pregnant patients in the POEM programme by contacting Janssen-Cilag Limited on 01494 567447 or at dsafety@its.jnj.com.
	• For more information, refer to the pregnancy reminder card for women of childbearing potential
	A pregnancy test is not applicable to this patient
	Counselling on pregnancy precautions is not applicable to this patient
Consi	derations relating to liver function
	Monitor patients who develop symptoms suggestive of hepatic dysfunction during treatment with PONVORY® for hepatotoxicity
	Discontinue treatment if significant liver injury is confirmed (e.g. alanine aminotransferase [ALT] exceeds 3× upper limit of normal [ULN] and total bilirubin exceeds 2×ULN)

Respiratory considerations		
	Perform spirometry evaluation of respiratory function during treatment with PONVORY® if clinically indicated	
Blood	Blood pressure considerations	
	Regularly monitor blood pressure during treatment with PONVORY®	
Neuro	Neurological considerations	
	Seizures have been reported in patients treated with PONVORY®. Physicians should be vigilant for seizures, especially in patients with a pre-existing history of seizures or a family history of epilepsy	
	Rare cases of posterior reversible encephalopathy syndrome (PRES) have been reported in patients receiving an S1P receptor modulator	
	 Promptly schedule a complete physical and neurological examination if a PONVORY®-treated patient develops unexpected neurological or psychiatric signs or symptoms, signs or symptoms suggestive of increased intracranial pressure, or accelerated neurological deterioration and an MRI should be considered 	
	Discontinue treatment with PONVORY® if PRES is suspected	
	• Symptoms of PRES are usually reversible but may evolve into ischaemic stroke or cerebral haemorrhage. Delay in diagnosis and treatment may lead to permanent neurological sequelae	
Additional considerations		
	Provide all patients with the patient/caregiver guide	
	Provide all patients with the pregnancy-specific patient reminder card if appropriate	

AFTER TREATMENT DISCONTINUATION

Peripheral blood lymphocyte counts		
	Vigilance for signs and symptoms of infection should be continued for 1-2 weeks after PONVORY® is discontinued	
Consi	Considerations relating to immunosuppressive effect	
	Exercise caution when co-administering anti-neoplastic, immune-modulating, or immunosuppressive therapies due to the risk of additive immune system effects. Caution should be applied during concomitant administration and up to 1 week after the last dose of PONVORY®	
Vaccines		
	Use of live attenuated vaccines may carry a risk of infection and should therefore be avoided during treatment and for up to 1 week after its discontinuation	
	 Counsel patients on the potential reduction in vaccine effectiveness and therefore avoid vaccination during treatment with PONVORY[®] and up to 1 week after its discontinuation 	
	• Treatment should not be resumed until 4 weeks after a planned vaccination if the use of live attenuated vaccine immunisation is required	
Ophthalmic evaluation		
	Consider the potential benefits and risks of PONVORY® after resolution of macular oedema before treatment re-initiation	

For women of childbearing potential	
	Counsel women of childbearing potential on the potential for serious risk to the foetus and the need for effective contraception during, and for 1 week after, stopping PONVORY® as it takes approximately 1 week to eliminate PONVORY® from the body
	 Consider the possible return of disease activity when stopping PONVORY[®] therapy for a planned pregnancy
	Provide medical advice regarding the risk of harmful effects to the foetus associated with PONVORY® treatment and ensure follow-up examinations are performed after discontinuation of treatment with PONVORY® if a woman becomes pregnant during treatment
Cardiac considerations	
	When treatment is interrupted if the resting heart rate (HR) is less than or equal to 55 bpm in patients receiving a stable dose of a beta-blocker, you can consider re-initiation with PONVORY® when:
	The baseline HR is greater than 55 bpm
Additional considerations	
	Observe patients for a severe exacerbation or return of high disease activity upon PONVORY® discontinuation and appropriate treatment should be instituted, as required

EM-82747 I December 2021 Marketing authorisation holder: Janssen-Cilag International NV, Turnhoutseweg 30, B-2340, Beerse, Belgium © 2021 Janssen Sciences Ireland UC